These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 30265242)

  • 21. Sofosbuvir and ribavirin for genotype 2 HCV infected patients with cirrhosis: A real life experience.
    Mangia A; Susser S; Piazzolla V; Agostinacchio E; De Stefano G; Palmieri V; Spinzi G; Carraturo I; Potenza D; Losappio R; Arleo A; Miscio M; Santoro R; Sarrazin C; Copetti M
    J Hepatol; 2017 Apr; 66(4):711-717. PubMed ID: 27965158
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interferon-free therapy with direct acting antivirals for HCV/HIV-1 co-infected Japanese patients with inherited bleeding disorders.
    Uemura H; Tsukada K; Mizushima D; Aoki T; Watanabe K; Kinai E; Teruya K; Gatanaga H; Kikuchi Y; Sugiyama M; Mizokami M; Oka S
    PLoS One; 2017; 12(10):e0186255. PubMed ID: 29045448
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patient with decompensated hepatitis C virus-related cirrhosis delisted for liver transplantation after successful sofosbuvir-based treatment.
    Ruiz I; Feray C; Pawlotsky JM; Hézode C
    Liver Transpl; 2015 Mar; 21(3):408-9. PubMed ID: 25420476
    [No Abstract]   [Full Text] [Related]  

  • 24. Defining the possibilities: is short duration treatment of chronic hepatitis C genotype 1 with sofosbuvir-containing regimens likely to be as effective as current regimens?
    Nafisi S; Roy S; Gish R; Manch R; Kohli A
    Expert Rev Anti Infect Ther; 2016; 14(1):41-56. PubMed ID: 26654939
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early virological response may predict treatment response in sofosbuvir-based combination therapy of chronic hepatitis c in a multi-center "real-life" cohort.
    Steinebrunner N; Sprinzl MF; Zimmermann T; Wörns MA; Zimmerer T; Galle PR; Stremmel W; Eisenbach C; Stein K; Antoni C; Schattenberg JM; Pathil A
    BMC Gastroenterol; 2015 Aug; 15():97. PubMed ID: 26239732
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of strategy-based approach to treatment of genotype 1 chronic hepatitis C.
    Zhao YJ; Khoo AL; Lin L; Teng M; Koh CJ; Lim SG; Lim BP; Dan YY
    J Gastroenterol Hepatol; 2016 Sep; 31(9):1628-37. PubMed ID: 26990023
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Baseline Factors Associated With Improvements in Decompensated Cirrhosis After Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection.
    El-Sherif O; Jiang ZG; Tapper EB; Huang KC; Zhong A; Osinusi A; Charlton M; Manns M; Afdhal NH; Mukamal K; McHutchison J; Brainard DM; Terrault N; Curry MP
    Gastroenterology; 2018 Jun; 154(8):2111-2121.e8. PubMed ID: 29535028
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improvement of liver function parameters in advanced HCV-associated liver cirrhosis by IFN-free antiviral therapies.
    Deterding K; Höner Zu Siederdissen C; Port K; Solbach P; Sollik L; Kirschner J; Mix C; Cornberg J; Worzala D; Mix H; Manns MP; Cornberg M; Wedemeyer H
    Aliment Pharmacol Ther; 2015 Oct; 42(7):889-901. PubMed ID: 26250762
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real life efficacy of ledipasvir/sofosbuvir in hepatitis C genotype 4-infected patients with advanced liver fibrosis and decompensated cirrhosis.
    Sanai FM; Altraif IH; Alswat K; AlZanbagi A; Babatin MA; AlMousa A; Almutairi NH; Aljawad MS; Alghamdi AS; Aljumah AA; Alalwan AM; Al-Hamoudi WK; Assiri AM; Dahlan Y; Alsahafi A; Alothmani HS; AlSaleemi MS; Mousa WA; Albenmousa A; Awny A; Albiladi H; Abdo AA; AlGhamdi H
    J Infect; 2018 Jun; 76(6):536-542. PubMed ID: 29742470
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interferon-free therapies for patients with chronic hepatitis C genotype 3 infection: A systematic review.
    Gimeno-Ballester V; Buti M; San Miguel R; Riveiro M; Esteban R
    J Viral Hepat; 2017 Nov; 24(11):904-916. PubMed ID: 27925386
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Unexpected Response Profiles Seen in Hepatitis C Virus-Infected Patients Treated with Sofosbuvir Plus Ribavirin: Five Case Reports.
    Saleem K; Wahid B; Ali A; Rafique S; Naz Z; Usman S; Idrees M
    Viral Immunol; 2018; 31(6):480-483. PubMed ID: 29694794
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma.
    Persico M; Aglitti A; Aghemo A; Rendina M; Lleo A; Ciancio A; Di Marco V; Lampertico P; Brunetto MR; Zuin M; Andreone P; Villa E; Troshina G; Calvaruso V; Degasperi E; Coco B; Giorgini A; Conti F; Di Leo A; Marzi L; Boccaccio V; Bollani S; Maisonneuve P; Bruno S
    Aliment Pharmacol Ther; 2018 Jun; 47(12):1705-1712. PubMed ID: 29722439
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and efficacy of simeprevir plus sofosbuvir with or without ribavirin in patients with decompensated genotype 1 hepatitis C cirrhosis.
    Modi AA; Nazario H; Trotter JF; Gautam M; Weinstein J; Mantry P; Barnes M; Habib A; McAfee J; Teachenor O; Tujague L; Gonzalez S
    Liver Transpl; 2016 Mar; 22(3):281-6. PubMed ID: 26335142
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study.
    Welzel TM; Nelson DR; Morelli G; Di Bisceglie A; Reddy RK; Kuo A; Lim JK; Darling J; Pockros P; Galati JS; Frazier LM; Alqahtani S; Sulkowski MS; Vainorius M; Akushevich L; Fried MW; Zeuzem S;
    Gut; 2017 Oct; 66(10):1844-1852. PubMed ID: 27418632
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The combination of simeprevir and sofosbuvir is more effective than that of peginterferon, ribavirin, and sofosbuvir for patients with hepatitis C-related Child's class A cirrhosis.
    Pearlman BL; Ehleben C; Perrys M
    Gastroenterology; 2015 Apr; 148(4):762-70.e2; quiz e11-2. PubMed ID: 25557952
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Eligibility and safety of the first interferon-free therapy against hepatitis C in a real-world setting.
    Höner Zu Siederdissen C; Maasoumy B; Deterding K; Port K; Sollik L; Mix C; Kirschner J; Cornberg J; Manns MP; Wedemeyer H; Cornberg M
    Liver Int; 2015 Jul; 35(7):1845-52. PubMed ID: 25556625
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of different sofosbuvir based treatment regimens on the biochemical profile of chronic hepatitis C genotype 4 patients.
    Elsharkawy A; Eletreby R; Fouad R; Soliman Z; Abdallah M; Negm M; Mohey M; Esmat G
    Expert Rev Gastroenterol Hepatol; 2017 Aug; 11(8):773-778. PubMed ID: 28480808
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High rates of hepatitis C virus (HCV) cure using direct-acting antivirals in HIV/HCV-coinfected patients: a real-world perspective.
    Hawkins C; Grant J; Ammerman LR; Palella F; Mclaughlin M; Green R; Mcgregor D; Stosor V
    J Antimicrob Chemother; 2016 Sep; 71(9):2642-5. PubMed ID: 27330060
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Twelve-week ribavirin-free direct-acting antivirals for treatment-experienced Chinese with HCV genotype 1b infection including cirrhotic patients.
    Ji D; Chen GF; Wang C; Wang YD; Shao Q; Li B; Zhao J; You SL; Hu JH; Liu JL; Niu XX; Chen J; Lu L; Wu V; Lau G
    Hepatol Int; 2016 Sep; 10(5):789-98. PubMed ID: 27443347
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).
    Bourlière M; Bronowicki JP; de Ledinghen V; Hézode C; Zoulim F; Mathurin P; Tran A; Larrey DG; Ratziu V; Alric L; Hyland RH; Jiang D; Doehle B; Pang PS; Symonds WT; Subramanian GM; McHutchison JG; Marcellin P; Habersetzer F; Guyader D; Grangé JD; Loustaud-Ratti V; Serfaty L; Metivier S; Leroy V; Abergel A; Pol S
    Lancet Infect Dis; 2015 Apr; 15(4):397-404. PubMed ID: 25773757
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.